Dean Sutherland, MD
Neurology · Sarasota, FLNPI 1346251089
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,754 of the $39,740 with a category attached, or 77.4%. 47 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 32.4% of the total. Reporting peaked in 2020 at $17,283 and has fallen 92.1% since, to $1,358 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 446 payments — averaging $89.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$13K
- Acorda Therapeutics, Inc$12K
- Sunovion Pharmaceuticals Inc.$7K
- AbbVie$2K
- Abbott$615
- GE HealthCare$541
- plus $5K from 41 others
Across 127 payments — averaging $241.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- MDD US Operations, LLC$31K
What the payments were for
- Speaking & faculty fees$30,75477%
- Food & beverage$8,98623%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,740 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 454 | $880,002 |
| NuplazidPimavanserin Tartrate | 104 | $760,566 |
| AustedoDeutetrabenazine | 40 | $284,961 |
| IngrezzaValbenazine Tosylate | 23 | $180,499 |
| NeuproRotigotine | 84 | $126,996 |
| InbrijaLevodopa | 34 | $102,776 |
| GocovriAmantadine Hcl | 32 | $92,413 |
| NourianzIstradefylline | 20 | $85,426 |
| Austedo XrDeutetrabenazine | 11 | $76,577 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,372 | $49,405 |
| Rasagiline Mesylate | 183 | $41,239 |
| BotoxOnabotulinumtoxina | 19 | $21,055 |
| Rivastigmine | 64 | $16,546 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 34 | $15,033 |
| AmantadineAmantadine Hcl | 195 | $12,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $12,875 | $880,002454 claims |
| Acadia Pharmaceuticals IncNuplazid | $265 | $760,566104 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $204 | $361,53851 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $460 | $180,49923 claims |
| UCB, Inc.Neupro | $525 | $126,99684 claims |
| Acorda Therapeutics, IncInbrija | $11,668 | $102,77634 claims |
| MDD US Operations, LLCGocovri | $334 | $92,41332 claims |
| Kyowa Kirin, Inc.Nourianz | $198 | $85,42620 claims |
| AbbVieBotox | $1,876 | $21,05519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Sarasota
- Donald NegroskiSarasota$1.4M
- Julio CanteroSarasota$811K
- Victor KassiciehSarasota$318K
- Gregory HanesSarasota$255K
- Maurico ConchaSarasota$212K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.